Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids: A Prospective Randomized Control Study

Chang Gung Medical Journal

Volumn 26, Issue 8, 2003, Pages 554-560

  Huang, Chung Jen ^b   Wang, Chun Hua ^b   Liu, Wen Te ^b   Yang, Mei Chen ^b   Lin, Horng Chyuan ^b   Yu, Chih Teng ^b   Shiao, Chia Jung ^b   Tan, Chia Chun ^b   Yang, Chao Kai ^b   Kuo, Han Pin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Leukotriene; Peak expiratory flow rate; St George's respiratory questionnaire

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID; ZAFIRLUKAST;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPIRATORY FLOW RATE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE LEVEL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TOSYL COMPOUNDS;

EID: 0142152629     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Samuelsson B, Dahlen JA, Lindgren CA. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
2. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
3. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast on cellular mediator of inflammation. Bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
4. Laitinen LA, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
5. Diamant Z, Hiltermann JT, Vanrensen EL, Callenbach PM, Veselic-Charvat MH, Veen VD, Sont JK, Sterk PJ. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-53.
6. Taylor IK, O'Shaughnessy KM, Fuller RM, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337: 690-4.
7. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor in patients with asthma: a randomized controlled trial. JAMA 1996;275: 931-6.
8. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002;165:861-6.
9. BJ. Leukotriene-receptor antagonists. Lancet 1999;353: 57-62.
10. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
11. Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000;55:478-83.
12. Horwitz RJ, Mcgill KA, Busse WW. The role of leukotriene modifier in the treatment of asthma. Am J Respir Crit Care Med 1998;157:1363-71.
13. Nathan RA, Bleecker ER, Kalberg C, Fluticasone Propionate Study Group. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 2001;111:195-202.
14. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
15. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8.
16. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF. Randomised placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
17. National Heart Lung and Blood Institute. Global strategy for asthma management and prevention, National Institute of Health 2002, publication No 02-3659.
18. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85:25-31.
19. Jones PW, Quirk FH, Baveystock CM. A self-complete measure of health status for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
20. In't Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000;161:1902-6.
21. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001;119:1021-6.
22. Simpson BM, Custovic A, Simpson A, Hallam CL, Walsh D, Marolia H. Risk factors for asthma and allergic disorders in adults. Clin Exp Allergy 2001;31:391-9.
23. Bousquet J, Hejjaoui A, Becker WM, Cour P, Chanal I, Lebel B. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. J Allergy Clin Immunol 1991;87:737-46.
24. 2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dir 1992:146:96-103.
25. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, Oates JA. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14.
26. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen KF, Holgate ST, Sampsson AP. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-46.
27. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promotor polymorphism and risk of aspirin-sensitive asthma. Lancet 1997;350:1599-600.
28. Virchow JC, Prasse JA, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85.